Christopher Vlasek
Family Medicine · Carson City, NVNPI 1518351089
Payments from drug & device makers
Across 163 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$307
- AstraZeneca$292
- Pfizer$241
- Lilly USA, LLC$126
- Novo Nordisk$118
- plus $516 from 15 others
What the payments were for
- Food & beverage$2,829100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 75 | $1,230 |
| Boehringer Ingelheim | 18 | $307 |
| AstraZeneca | 15 | $292 |
| Pfizer | 14 | $241 |
| Lilly USA, LLC | 6 | $126 |
| Novo Nordisk | 7 | $118 |
| AbbVie | 6 | $108 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Sanofi | 2 | $38 |
| Amgen | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Abbott | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Eisai Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$2,829 in reported general payments places this provider in the 80th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 83 | $169,653 |
| FarxigaDapagliflozin Propanediol | 107 | $156,172 |
| EliquisApixaban | 113 | $152,841 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 116 | $144,612 |
| JardianceEmpagliflozin | 75 | $125,021 |
| RybelsusSemaglutide | 42 | $77,600 |
| MounjaroTirzepatide | 26 | $56,236 |
| OzempicSemaglutide | 26 | $40,520 |
| XareltoRivaroxaban | 22 | $32,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $28,677 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $25,595 |
| JanuviaSitagliptin Phosphate | 15 | $23,600 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $17,642 |
| NexlizetBempedoic Acid/Ezetimibe | 17 | $17,486 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $13,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $126 | $225,889109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $292 | $184,849129 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,230 | $175,941147 claims |
| PfizerEliquis | $241 | $152,841113 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Pradaxa | $307 | $152,709118 claims |
| Novo NordiskRybelsus, Ozempic | $118 | $118,12068 claims |
| Esperion Therapeutics, Inc.Nexlizet | $48 | $17,48617 claims |
| AbbVieSynthroid | $108 | $10,02498 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 902 family medicine providers in Nevada.
Other family medicine in Carson City
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Susan ParkReno$1.1M
- Sangeeta WagnerSparks$880K
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.